Clinical trial · Interventional
Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings
NCT06528184CI-TRIAL-00085701recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone. The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinician-sampled HPV DNA test | Diagnostic Test | — | UNRESOLVED |
| Self-sampled HPV DNA testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Usual care arm
- description
- Participants will only be offered clinician-sampling for HPV DNA testing to determine if they are agreeable to undergo screening.
- interventionNames
- Diagnostic Test: Clinician-sampled HPV DNA test
- type
- EXPERIMENTAL
- label
- Intervention arm
- description
- Participants will be offered clinician-sampling or self-sampling for HPV DNA testing to determine if they are agreeable to undergo screening using either modality.
- interventionNames
- Diagnostic Test: Self-sampled HPV DNA testing
- Diagnostic Test: Clinician-sampled HPV DNA test
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * 30-69 years old female Singapore citizens * Due for cervical cancer screening * Engaged in sexual intercourse before * Able to give informed consent * Able to read and communicate in English, Chinese or Malay Exclusion Criteria: * Virgo intacta * Pregnancy * History of cervical cancer, precancerous cervical lesions and total hysterectomy
References
Publications (1)
- DERIVEDNg XR, Quek IP, Pereira MJ, Molina JA, Ngeow J, Wong SKW. Randomised controlled trial evaluating the impact of different methods of HPV DNA testing for cervical cancer screening in Singapore's primary care settings: a study protocol. BMJ Open. 2025 Mar 24;15(3):e095091. doi: 10.1136/bmjopen-2024-095091. PMID 40132819